Topics covered include are payers helping or hindering biosimilar market access as well as can MCDA ...
Read moreMulti-criteria decision analysis (MCDA) is a potentially useful tool that can be used to support dec...
Read moreThe German Ministry of Health has recently published its final bill concerning pricing and market ac...
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read more2025 was a pivotal year for market access, marked by the growing convergence between scientific inno...
Read moreThe pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t...
Read moreOur review of the 2024 pricing and market access revealed key challenges facing the pharmaceutical i...
Read moreRemap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...
Read moreRemap Consulting guides participants through the intricacies of incorporating EU HTA considerations ...
Read moreWebinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...
Read more